TrialsgrambetaRCTs are beautiful

SGEM#325: Thin Ice – Subgroup Analysis of the THAWS Trial

10 ensayos

Ensayos extraídos del pódcast de Dr. Ken Milne

  • 2021THAWSAnticoagulation & AntithromboticsIn126 patients with unknown-onset ischemic stroke and DWI-FLAIR mismatch,low-dose alteplasewas compared withstandard medical treatmentfordisability-free outcome at 90 days.
  • 2020THAWSAnticoagulation & AntithromboticsIn 131 patients with unknown-onset stroke and DWI-FLAIR mismatch, intravenous alteplase did not improve 90-day mRS 0-1 versus standard antithrombotic care.
  • 2018WAKE-UPAnticoagulation & AntithromboticsIn 503 patients with acute ischaemic stroke of unknown onset and DWI-FLAIR mismatch, intravenous alteplase improved functional outcome at 90 days compared with placebo.
  • 2016ENCHANTEDAnticoagulation & AntithromboticsIn 3310 patients with acute ischaemic stroke, low-dose alteplase was not non-inferior to standard-dose alteplase for death or disability at 90 days.
  • 2017Mechanical Thrombectomy Outcomes With and Without Intravenous Thrombolysis in Stroke PatientsAnticoagulation & AntithromboticsIn 2943 patients with acute ischemic stroke, thrombectomy after intravenous thrombolysis improved functional independence compared with thrombectomy alone.
  • 2020DIRECT-MTAnticoagulation & AntithromboticsIn 656 patients with large-vessel-occlusion stroke, thrombectomy alone was noninferior for 90-day disability compared with thrombectomy after alteplase.
  • 2021SKIPAnticoagulation & AntithromboticsIn 204 patients with large-vessel-occlusion stroke, thrombectomy alone was not non-inferior for 90-day functional independence versus alteplase plus thrombectomy.
  • 2021DEVTAnticoagulation & AntithromboticsIn 234 patients with anterior-circulation large-vessel occlusion, thrombectomy alone was non-inferior to bridging alteplase for 90-day functional independence.
  • 2020ECASS III reanalysisAnticoagulation & AntithromboticsIn 821 adults with acute ischaemic stroke treated 3-4.5 hours after onset, alteplase did not improve disability-free survival at 90 days compared with placebo.
  • 2020EOSAnticoagulation & AntithromboticsIn 843 patients with stroke of unknown onset and imaging mismatch, intravenous alteplase improved 90-day functional outcome compared with placebo or standard care.